SAHIT Investigators-on the Outcome of Some Subarachnoid Hemorrhage Clinical Trials

Translational Stroke Research

Volumn 4, Issue 3, 2013, Pages 286-296

  Macdonald, R Loch ^a,k   Jaja, Blessing ^a   Cusimano, Michael D ^a   Etminan, Nima ^b   Hanggi, Daniel ^b   Hasan, David ^c   Ilodigwe, Don ^a   Lantigua, Hector ^d   Le Roux, Peter ^e   Lo, Benjamin ^a   Louffat Olivares, Ada ^a   Mayer, Stephan ^d   Molyneux, Andrew ^f   Quinn, Audrey ^g   Schweizer, Tom A ^a   Schenk, Thomas ^h   Spears, Julian ^a   Todd, Michael ^c   Torner, James ^c   Vergouwen, Mervyn D I ⁱ   Wong, George K C ^j   Singh, Jeff ^l   more..

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Department of Orthopedic Surgery   (Germany)

^c UNIVERSITY OF IOWA   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g LEEDS GENERAL INFIRMARY   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

Clinical trial; Outcome; Subarachnoid hemorrhage

Indexed keywords

CLAZOSENTAN; MAGNESIUM; NICARDIPINE; NIMODIPINE; TIRILAZAD;

BLOOD PRESSURE; BRAIN VASOSPASM; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); GLASGOW OUTCOME SCALE; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; REVIEW; SAMPLE SIZE; SUBARACHNOID HEMORRHAGE;

ANTIOXIDANTS; BRAIN INFARCTION; CALCIUM CHANNEL BLOCKERS; CRITICAL CARE; DIOXANES; DRUG THERAPY, COMBINATION; HUMANS; HYPOTENSION; INTRACRANIAL ANEURYSM; MAGNESIUM COMPOUNDS; NEUROPROTECTIVE AGENTS; NICARDIPINE; NIMODIPINE; PHYSICIAN'S PRACTICE PATTERNS; PREGNATRIENES; PYRIDINES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; SAMPLE SIZE; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; TREATMENT OUTCOME; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 84877149778     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0242-1     Document Type: Review

References (80)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011; 123: e18-e209.
2. Prevalence of stroke-United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2012; 61: 379-82.
3. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009; 8: 355-69.
4. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007; 78: 1365-72.
5. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996; 27: 1459-66.
6. Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010; 41: e519-36.
7. Bendel P, Koivisto T, Niskanen E, Kononen M, Aikia M, Hanninen T, et al. Brain atrophy and neuropsychological outcome after treatment of ruptured anterior cerebral artery aneurysms: a voxel-based morphometric study. Neuroradiology. 2009; 51: 711-22.
8. King Jr JT, DiLuna ML, Cicchetti DV, Tsevat J, Roberts MS. Cognitive functioning in patients with cerebral aneurysms measured with the mini mental state examination and the telephone interview for cognitive status. Neurosurgery. 2006; 59: 803-10.
9. Otawara Y, Ogasawara K, Kubo Y, Kashimura H, Ogawa A, Yamadate K. Comparison of postoperative cognitive function in patients undergoing surgery for ruptured and unruptured intracranial aneurysm. Surg Neurol. 2009; 72: 592-5.
10. Bellebaum C, Schafers L, Schoch B, Wanke I, Stolke D, Forsting M, et al. Clipping versus coiling: neuropsychological follow up after aneurysmal subarachnoid haemorrhage (SAH). J Clin Exp Neuropsychol. 2004; 26: 1081-92.
11. Hadjivassiliou M, Tooth CL, Romanowski CA, Byrne J, Battersby RD, Oxbury S, et al. Aneurysmal SAH: cognitive outcome and structural damage after clipping or coiling. Neurology. 2001; 56: 1672-7.
12. Fontanella M, Perozzo P, Ursone R, Garbossa D, Bergui M. Neuropsychological assessment after microsurgical clipping or endovascular treatment for anterior communicating artery aneurysm. Acta Neurochir (Wien). 2003; 145: 867-72.
13. Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, et al. Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke. 2002; 33: 200-8.
14. Mavaddat N, Sahakian BJ, Hutchinson PJ, Kirkpatrick PJ. Cognition following subarachnoid hemorrhage from anterior communicating artery aneurysm: relation to timing of surgery [see comments]. J Neurosurg. 1999; 91: 402-7.
15. Hillis AE, Anderson N, Sampath P, Rigamonti D. Cognitive impairments after surgical repair of ruptured and unruptured aneurysms. J Neurol Neurosurg Psychiatry. 2000; 69: 608-15.
16. Manning L, Pierot L, Dufour A. Anterior and non-anterior ruptured aneurysms: memory and frontal lobe function performance following coiling. Eur J Neurol. 2005; 12: 466-74.
17. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology. 2010; 74: 1494-501.
18. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007; CD000277.
19. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989; 298: 636-42.
20. Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. 2002; 360: 1267-74.
21. Deans KJ, Minneci PC, Suffredini AF, Danner RL, Hoffman WD, Ciu X, et al. Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med. 2007; 35: 1509-16.
22. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med. 2010; 38: S534-8.
23. Maas AI, Menon DK, Lingsma HF, Pineda JA, Sandel ME, Manley GT. Re-orientation of clinical research in traumatic brain injury: report of an international workshop on comparative effectiveness research. J Neurotrauma. 2012; 29: 32-46.
24. Maas AI, Marmarou A, Murray GD, Teasdale SG, Steyerberg EW. Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. J Neurotrauma. 2007; 24: 232-8.
25. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke. 2007; 38: 1911-5.
26. Dachs RJ, Burton JH, Joslin J. A user's guide to the NINDS rt-PA stroke trial database. PLoS Med. 2008; 5: e113.
27. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, et al. The Virtual International Stroke Trials Archive. Stroke. 2007; 38: 1905-10.
28. Ali M, Bath P, Brady M, Davis S, Diener HC, Donnan G, et al. Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke. 2012; 7: 133-8.
29. Sahs AL, Perret GE, Locksley HB, Nishioka H, Skultety FM. Intracranial aneurysms and subarachnoid hemorrhage. Philadelphia: Lippincott; 1969.
30. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007; 38: 3055-62.
31. Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009; 10: 141-7.
32. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2010; 2: CD006778.
33. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998; 15: 573-85.
34. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011; 31: 1443-51.
35. van den Bergh WM, Albrecht KW, van der Sprenkel JW B, Rinkel GJ. Magnesium therapy after aneurysmal subarachnoid haemorrhage a dose-finding study for long term treatment. Acta Neurochir (Wien). 2003; 145: 195-9.
36. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002; 96: 510-4.
37. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010; 41: 921-6.
38. Mees SM, Algra A, Vandertop WP, van KF, Kuijsten HA, Boiten J, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012.
39. Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006; 26: 1341-53.
40. Sehba FA, Bederson JB. Mechanisms of acute brain injury after subarachnoid hemorrhage. Neurol Res. 2006; 28: 381-98.
41. Pluta RM, Hansen-Schwartz J, Dreier J, Vajkoczy P, Macdonald RL, Nishizawa S, et al. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res. 2009; 31: 151-8.
42. Jaja BN, Cusimano MD, Etminan N, Hanggi D, Hasan D, Ilodigwe D, et al. Clinical prediction models for aneurysmal subarachnoid hemorrhage: a systematic review. Neurocrit Care. 2012. doi: 10. 1007/s12028-012-9792-z.
43. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008; 69: 33-9.
44. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van GJ. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988; 19: 604-7.
45. Ilodigwe D, Stat M, Murray GD, Kassell NF, Torner J, Kerr RS, et al. Sliding dichotomy compared with fixed dichotomization of ordinal outcome scales in subarachnoid hemorrhage trials. J Neurosurg. 2012.
46. Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, et al. Design and analysis of phase 3 trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma. 2005; 22: 511-7.
47. Scales DC, Rubenfeld GD. Estimating sample size in critical care clinical trials. J Crit Care. 2005; 20: 6-11.
48. Meinert CL, Tonascia S. Clinical trials. Design, conduct, and analysis. New York: Oxford University Press; 1986.
49. Kreiter KT, Mayer SA, Howard G, Knappertz V, Ilodigwe D, Sloan MA, et al. Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke. 2009; 40: 2362-7.
50. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008; 39: 3015-21.
51. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012; 43: 1171-8.
52. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, et al. Enhancing the development and approval of acute stroke therapies: stroke therapy academic industry roundtable. Stroke. 2005; 36: 1808-13.
53. Jennett B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet. 1975; 1: 480-4.
54. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012; 43: 1463-9.
55. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011; 10: 618-25.
56. Le Roux PD, Elliott JP, Newell DW, Grady MS, Winn HR. Predicting outcome in poor-grade patients with subarachnoid hemorrhage: a retrospective review of 159 aggressively managed cases. J Neurosurg. 1996; 85: 39-49.
57. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2011; 31: 1545-53.
58. Fergusen S, Macdonald RL. Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007; 60: 658-67.
59. Ohman J, Servo A, Heiskanen O. Risk factors for cerebral infarction in good-grade patients after aneurysmal subarachnoid hemorrhage and surgery: a prospective study. J Neurosurg. 1991; 74: 14-20.
60. Connolly Jr ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012; 43: 1711-37.
61. Dreier JP, Windmuller O, Petzold G, Lindauer U, Einhaupl KM, Dirnagl U. Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery. 2002; 51: 1457-65.
62. Vergouwen MD, Vermeulen M, de Haan RJ, Levi M, Roos YB. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab. 2007; 27: 1293-308.
63. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, et al. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke. 2012; 43: 1163-70.
64. Hall CE, Mirski M, Palesch YY, Diringer MN, Qureshi AI, Robertson CS, et al. Clinical trial design in the neurocritical care unit. Neurocrit Care. 2011. 16(1): 6-19. doi: 10. 1007/s12028-011-9608-6.
65. Schellinger PD, Bath PM, Lees KR, Bornstein NM, Uriel E, Eisert W, et al. Assessment of additional endpoints for trials in acute stroke-what, when, where, in who? Int J Stroke. 2012; 7: 227-30.
66. Duncan PW, Jorgensen HS, Wade DT. Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke. 2000; 31: 1429-38.
67. Haley Jr EC, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993; 78: 537-47.
68. Haley ECJ, Kassell NF, Torner JC, Truskowski LL, Germanson TP. A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg. 1994; 80: 788-96.
69. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care. 2010; 13: 416-24.
70. Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. 2012; 43: 2671-6.
71. Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, et al. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008; 3: 130-7.
72. Broderick JP, Meyers PM. Acute stroke therapy at the crossroads. JAMA. 2011; 306: 2026-8.
73. Disney L, Weir B, Grace M, Roberts P. Trends in blood pressure, osmolality and electrolytes after subarachnoid hemorrhage from aneurysms. Can J Neurol Sci. 1989; 16: 299-304.
74. Kasuya H. Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo. Acta Neurochir Suppl. 2011; 110: 165-7.
75. Cook DJ, Kan S, Ai J, Kasuya H, Macdonald RL. Cisternal sustained release dihydropyridines for subarachnoid hemorrhage. Curr Neurovasc Res. 2012; 9: 139-48.
76. Tobin MJ. Counterpoint: evidence-based medicine lacks a sound scientific base. Chest. 2008; 133: 1071-4.
77. van der Shaaf I, Ruigrok YM, Rinkel GJ, Algra A, van Gijn J. Study design and outcome measures in studies on aneurysmal subarachnoid hemorrhage. Stroke. 2002; 33: 2043-6.
78. Marmarou A, Lu J, Butcher I, McHugh GS, Mushkudiani NA, Murray GD, et al. IMPACT database of traumatic brain injury: design and description. J Neurotrauma. 2007; 24: 239-50.
79. Myzoon A, Bath P, Brady M, Davis S, Diener HC, Donnan G, et al. Development, expansion, and use of a stroke clinical trials resource for novel exploratory analyses. Int J Stroke. 2012; 7: 133-8.
80. Frontera JA, Fernandez A, Schmidt JM, Claassen J, Wartenberg KE, Badjatia N, et al. Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke. 2009; 40: 1963-8.